Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Thermo Fisher Scientific Inc (NASDAQ:TMO) Executive Vice President Michael D. Shafer sold 10,725 shares of common stock on November 25, 2025, for $600.00 each, totaling $6.43 million. The sales were executed under a Rule 10b5-1 trading plan adopted November 20, 2024.
On the same day, Shafer also exercised options to acquire 10,725 shares of Thermo Fisher Scientific common stock. These transactions involved two separate option exercises, with 8,475 shares acquired at $253.99 each and 2,250 shares acquired at $294.02 each, for a total value of $2814110.
Following these transactions, Shafer directly owns 18730.8026 shares of Thermo Fisher Scientific Inc.
In other recent news, Thermo Fisher Scientific Inc. has announced a €2.1 billion notes offering through its finance subsidiary, Thermo Fisher Scientific (Finance I) B.V. This includes €1 billion of floating rate senior notes due in 2027 and €1.1 billion of 3.628% senior notes due in 2035. Moody’s Ratings has upgraded Thermo Fisher Scientific’s senior unsecured notes to A2 from A3, reflecting solid operating performance despite macroeconomic challenges. In addition, Thermo Fisher has received FDA clearance for its new diagnostic system, the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay, aimed at detecting multiple myeloma. The company has also announced a $5 billion share repurchase program, with no expiration date, to be conducted through open market or negotiated transactions. Furthermore, Thermo Fisher’s Board of Directors has authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.